Pfizer's stock has seen a dramatic decline, down over 11% year-to-date and more than 20% in the past year, largely due to changes in COVID-19 vaccine recommendations. The FDA's decision to limit recommendations to seniors and individuals with specific medical conditions poses a significant challenge for Pfizer's COVID-related revenues. Despite strong sales in 2024 from both COVID and non-COVID products, the company is trying to stabilize its revenue forecasts for 2025, looking towards new drugs and an increasing oncology pipeline to drive growth amidst declining COVID sales.
Pfizer forecasts FY 2025 total revenues between $61 billion and $64 billion, with newly acquired drugs filling the gap for lagging COVID products such as Paxlovid.
Over the past five years, the stock has let shareholders down despite paying a dividend with a current and substantial yield of 7.31%.
The FDA's new recommendations limit COVID-19 vaccines to seniors and those with specific health conditions, posing a significant challenge for Pfizer's revenue from COVID products.
Shares of Pfizer have experienced a notable decline, down more than 60% from their all-time high in December 2021, signaling investor concern.
Collection
[
|
...
]